This site is intended for healthcare professionals

Phase II trials and stem cell therapies

Read time: 10 mins
Last updated:2nd Sep 2020
Published:2nd Sep 2020
What drug therapies on the horizon for NASH? Discover range of treatments currently in phase II trials and the trials that didn’t make it to phase III. Also learn about the potential for stem cell therapies in treating NASH.

There are more than a dozen or so treatments in Phase II trials, including agonists for PPAR and farnesoid X receptors, such as Enanta’s EDP 305.

Enanta plans to start a further Phase III trial ARGON-2 in NASH in early Q2 2020 and start a Phase I study of EDP 297 as a follow up FXR agonist.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.